Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of targeted therapies for cancer treatment. The company's lead product candidate, THE-630, is a pan-KIT inhibitor designed for the treatment of gastrointestinal stromal tumors and is currently in Phase I clinical trial. Additionally, Theseus Pharmaceuticals is developing a fourth-generation EGFR inhibitor to address drug resistance mutations in non-small cell lung cancer patients. The company's focus on developing therapies targeting key driver oncogenes aims to address the growing need for effective treatments for cancer patients.

Products

• THE-630 - pan-KIT inhibitor for gastrointestinal stromal tumors

• Fourth-generation EGFR inhibitor for non-small cell lung cancer